It is very uncertain whether infliximab changes serious adverse events (at 54 weeks) compared with placebo (very low certainty).
Vedolizumab showed no clear difference in serious adverse events (52–60 weeks) compared with placebo (low certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
Two infusions of natalizumab (6 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
Three infusions of natalizumab (300 mg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in serious adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
It is very uncertain whether methotrexate + infliximab changes serious adverse events (Schröder 2006) compared with infliximab alone (very low certainty).
Briakinumab showed no clear difference in serious adverse events (Panaccione 2010) compared with placebo (low certainty).
Summary of findings table ‐ Stem Cell showed no clear difference in serious Adverse Events compared with placebo or Control (low certainty).
It is very uncertain whether infliximab combined with purine analogues changes serious adverse events (at 48 weeks to 2 years) compared with purine analogues (very low certainty).
Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).
The review found no eligible studies for this question.
Antibiotic showed no clear difference in serious adverse events compared with placebo (low certainty).